Differentiation of Alzheimer's Disease from Other Neurodegenerative Disorders Using Chemiluminescence Immunoassays Measuring Cerebrospinal Fluid Biomarkers

Overview

Journal Front Dement

Date 2024 Oct 16

PMID 39410947

Authors

Philipp Arendt

Katharina Rompler

Britta Brix

Viola Borchardt-Loholter

Mandy Busse

Stefan Busse

Affiliations

Soon will be listed here.

Abstract

Introduction: Prior research identified four neurochemical cerebrospinal fluid (CSF) biomarkers, Aβ1-42, Aβ1-40, tTau, and pTau(181), as core diagnostic markers for Alzheimer's disease (AD). Determination of AD biomarkers using immunoassays can support differential diagnosis of AD vs. several neuropsychiatric disorders, which is important because the respective treatment regimens differ. Results of biomarker determination can be classified according to the Amyloid/Tau/Neurodegeneration (ATN) system into profiles. Less is known about the clinical performance of chemiluminescence immunoassays (ChLIA) measuring specific biomarkers in CSF samples from patients suffering from neuropsychiatric impairments with various underlying causes.

Methods: Chemiluminescence immunoassays (ChLIAs, EUROIMMUN) were used to determine Beta-Amyloid (1-40), Beta-Amyloid (1-42), Total-Tau, and pTau(181) concentrations in precharacterized cerebrospinal fluid (CSF) samples from 219 AD patients, 74 patients with mild cognitive impairment (MCI), and 220 disease control (DC) patients.

Results: 83.0% of AD patients had ATN profiles consistent with AD, whereas 85.5% of DC patients and 77.0% of MCI patients had profiles inconsistent with AD. AD patients showed significantly lower amyloid ratio Aβ1-42/Aβ1-40 (mean: 0.07) and significantly higher concentrations of tTau (mean: 901.6 pg/ml) and pTau(181) (mean: 129 pg/ml) compared to DC and MCI patients (all values < 0.0071).

Discussion: The ChLIAs effectively determined specific biomarkers and can support differential diagnostics of AD. Their quality was demonstrated in samples from 513 patients with cognitive impairments, representing a realistic mix of underlying causes for seeking treatment at a memory clinic.

References

Agnello L, Piccoli T, Vidali M, Cuffaro L, Lo Sasso B, Iacolino G . Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis. Scand J Clin Lab Invest. 2020; 80(4):313-317. DOI: 10.1080/00365513.2020.1740939. View

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

Hulsen T, de Vlieg J, Alkema W . BioVenn - a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams. BMC Genomics. 2008; 9:488. PMC: 2584113. DOI: 10.1186/1471-2164-9-488. View

Ismail Z, Smith E, Geda Y, Sultzer D, Brodaty H, Smith G . Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement. 2015; 12(2):195-202. PMC: 4684483. DOI: 10.1016/j.jalz.2015.05.017. View

Bayart J, Hanseeuw B, Ivanoiu A, van Pesch V . Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ and T-Tau assays for Alzheimer's disease diagnosis. J Neurol. 2019; 266(9):2304-2311. DOI: 10.1007/s00415-019-09418-6. View

Chen G, Xu T, Yan Y, Zhou Y, Jiang Y, Melcher K . Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin. 2017; 38(9):1205-1235. PMC: 5589967. DOI: 10.1038/aps.2017.28. View

Bouwman F, Frisoni G, Johnson S, Chen X, Engelborghs S, Ikeuchi T . Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios. Alzheimers Dement (Amst). 2022; 14(1):e12314. PMC: 9044123. DOI: 10.1002/dad2.12314. View

Kuring J, Mathias J, Ward L . Prevalence of Depression, Anxiety and PTSD in People with Dementia: a Systematic Review and Meta-Analysis. Neuropsychol Rev. 2018; 28(4):393-416. DOI: 10.1007/s11065-018-9396-2. View

Niemantsverdriet E, Ottoy J, Somers C, De Roeck E, Struyfs H, Soetewey F . The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting. J Alzheimers Dis. 2017; 60(2):561-576. PMC: 5611891. DOI: 10.3233/JAD-170327. View

10.

Blennow K, Zetterberg H . Biomarkers for Alzheimer's disease: current status and prospects for the future. J Intern Med. 2018; 284(6):643-663. DOI: 10.1111/joim.12816. View

11.

Cummings J . The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases. Am J Geriatr Psychiatry. 2020; 29(4):375-383. PMC: 7855689. DOI: 10.1016/j.jagp.2020.07.011. View

12.

Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P . Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease. Alzheimers Res Ther. 2019; 11(1):34. PMC: 6477717. DOI: 10.1186/s13195-019-0485-0. View

13.

Jack Jr C, Bennett D, Blennow K, Carrillo M, Feldman H, Frisoni G . A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016; 87(5):539-47. PMC: 4970664. DOI: 10.1212/WNL.0000000000002923. View

14.

Sperling R, Aisen P, Beckett L, Bennett D, Craft S, Fagan A . Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):280-92. PMC: 3220946. DOI: 10.1016/j.jalz.2011.03.003. View

15.

Dafsari F, Jessen F . Depression-an underrecognized target for prevention of dementia in Alzheimer's disease. Transl Psychiatry. 2020; 10(1):160. PMC: 7239844. DOI: 10.1038/s41398-020-0839-1. View

16.

Buchhave P, Minthon L, Zetterberg H, Wallin A, Blennow K, Hansson O . Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012; 69(1):98-106. DOI: 10.1001/archgenpsychiatry.2011.155. View

17.

. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018; 18(1):88-106. PMC: 6291454. DOI: 10.1016/S1474-4422(18)30403-4. View

18.

Polykretis P, Banchelli M, DAndrea C, de Angelis M, Matteini P . Raman Spectroscopy Techniques for the Investigation and Diagnosis of Alzheimer's Disease. Front Biosci (Schol Ed). 2022; 14(3):22. DOI: 10.31083/j.fbs1403022. View

19.

Bjerke M, Engelborghs S . Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis. J Alzheimers Dis. 2018; 62(3):1199-1209. PMC: 5870045. DOI: 10.3233/JAD-170680. View

20.

Leitao M, Silva-Spinola A, Santana I, Olmedo V, Nadal A, Le Bastard N . Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease. Alzheimers Res Ther. 2019; 11(1):91. PMC: 6875031. DOI: 10.1186/s13195-019-0550-8. View